Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation of our earlier intimation dated August 14, 2025, please find enclosed ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries Ltd (SPIL) is buying an operational API (Active Pharmaceutical Ingredient) manufacturing facility from Srigen Lifesciences for Rs. 25.5 crores. The facility is located in Telangana and includes land, building, and plant & machinery. Srigen operates an 80-kilolitre reactor capacity plant and has over 50 KSMs/intermediates in its portfolio. With this acquisition, SPIL will gain the ability to manufacture complex, high-margin molecules like Ropivacaine, Bupivacaine, Probenecid, Sitagliptin, Apixaban, and Rivaroxaban. The company expects the move to accelerate its entry into the API and specialty chemicals space with shorter product launch timelines. This follows an earlier intimation dated August 14, 2025.
This is a significant capacity-expansion move that should support future revenue and margin growth. The acquisition signals a push into higher-value, regulated-market APIs and could be a positive trigger for the stock as it strengthens SPIL's manufacturing backbone and global competitiveness.